Morbidity low with focal laser ablation of prostate cancer

Morbidity low with focal laser ablation of prostate cancer

(HealthDay)—Focal laser ablation (FLA) of low- to intermediate-risk prostate cancer is associated with low morbidity and good oncologic outcomes, according to a study published in the March issue of the Journal of Vascular and Interventional Radiology.

Eric Walser, M.D., from the University of Texas Medical Branch in Galveston, and colleagues conducted transrectal FLA in 120 with low-risk to intermediate-risk prostate cancer. Ablation was controlled by imaging (MRI) thermometry. At six and 12 months, clinical and MRI follow-up was performed with biopsy of suspicious areas. Sexual and urinary function were surveyed.

The researchers found that 30.8, 46.7, and 22.5 percent of patients had a Gleason score of 3+3=6, 3+4=7, and 4+3=7, respectively. Tumor stage was T1c, T2a, and T2b in 74.2, 21.7, and 4.2 percent of patients, respectively. Seventeen percent of patients had additional oncologic therapy one year after FLA when cancer was confirmed by biopsy following abnormal MRI. No difference was seen in functional scores before and after ablation. At 12 months, median prostate-specific antigen levels decreased significantly to 3.25. The only significant predictor for positive MRI after treatment was tumor diameter above the median (odds ratio, 3.36).

"Data from this group of 120 patients who had FLA for prostate cancer show promising early oncologic results without in quality of life and acceptable morbidity in patients with low- to intermediate-risk disease," the authors write.


Explore further

Laser-targeted removal of prostate tumors works as well complete removal of prostate

More information: Abstract/Full Text (subscription or payment may be required)

Copyright © 2019 HealthDay. All rights reserved.

Citation: Morbidity low with focal laser ablation of prostate cancer (2019, April 12) retrieved 25 June 2019 from https://medicalxpress.com/news/2019-04-morbidity-focal-laser-ablation-prostate.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more